Key Takeaways:
- BRAFTOVI combo cut progression risk by 56 percent vs standard chemo in first-line mCRC
- Median PFS reached 15.2 months vs 8.3 months for the control arm
- FDA granted full approval in February 2026 for the expanded indication
Back
Pfizer BRAFTOVI regimen nearly doubles PFS in BRAF V600E mCRC trial
Pfizer's BRAFTOVI (encorafenib) in combination with cetuximab and FOLFIRI nearly doubled median progression-free survival to 15.2 months in previously untreated BRAF V600E-mutant metastatic colorectal cancer, a 56 percent reduction in the risk of progression or death versus standard chemotherapy.
"The results strengthen confidence in how we can treat this disease," Scott Kopetz, professor and deputy chair of gastrointestinal medical oncology at MD Anderson Cancer Center and co-principal investigator of the BREAKWATER trial, said in a statement. A 56 percent reduction in risk of disease progression or death, combined with prolonged overall survival, reinforces the regimen as a standard of care in the first-line setting, he said.
The Phase 3 BREAKWATER trial's Cohort 3 randomized 147 patients to receive either BRAFTOVI plus cetuximab and FOLFIRI or FOLFIRI with or without bevacizumab. The hazard ratio for PFS was 0.44 (95 percent CI, 0.27 to 0.70; p equals 0.0002), meaning the result has less than a 0.1 percent chance of being random. Overall survival showed a 44 percent reduction in the risk of death (HR 0.56; 95 percent CI, 0.34 to 0.94) with a median follow-up of about 20 months in both arms. At 18 months, 72 percent of patients on the BRAFTOVI regimen were alive versus 54.5 percent on the control. Median OS was not reached for the treatment arm versus 20.3 months for the comparator.
Grade 3 or higher adverse events occurred in 70.4 percent of patients receiving the BRAFTOVI combination versus 80.9 percent on standard therapy. The most common side effects included nausea, diarrhea, vomiting, anemia, and fatigue. Treatment discontinuation due to adverse events was 15.5 percent in the treatment arm versus 10.3 percent in the control. No new safety signals were identified, Pfizer said.
BRAF V600E mutations occur in 8 percent to 12 percent of metastatic colorectal cancer patients and are associated with more than double the risk of mortality versus patients with no known mutation. Before the FDA's accelerated approval in December 2024, no biomarker-driven therapies were specifically indicated for this population. The FDA granted full approval in February 2026 based on the totality of BREAKWATER data, allowing flexibility in the choice of chemotherapy backbone.
"These compelling results add to a strong body of evidence demonstrating the efficacy of the BRAFTOVI combination treatment across two different established chemotherapy regimens," Jeff Legos, chief oncology officer at Pfizer, said. The findings reaffirm the regimen as a cornerstone of first-line treatment, he said.
The results position the BRAFTOVI triplet regimen as a standard of care for this molecular subtype, which affects about 15,000 to 20,000 new patients annually in the US alone. Investors will watch for updated NCCN guidelines and potential label expansions into additional chemotherapy combinations.
This article is for informational purposes only and does not constitute investment advice.
